Dr. Bloomgarden reviews recent trial data (ie, ACCORD, ADVANCE, VA diabetes trial), and examines different safety issues that must be taken into account in determining how intensive a glycemic intervention be considered.

Part 4. Are There Methodologic Issues with Measuring HbA1c?

Sep 30th, 2010 1m 19s

Dr. Bloomgarden briefly synopsizes laboratory test variability with regard to measuring HbA1c levels.

Part 3. Should HbA1c Be Used in the Diagnosis of T2DM?

Sep 30th, 2010 3m 19s

In Part 3 of this podcast, the discussion surrounds the International Expert Committee's recommendations, which has been taken up by the American Diabetes Association, to suggest that 6.5 be used for the diagnosis of diabetes. Dr. Bloomgarden o

Part 2. Does HbA1c Provide a True Average Glucose Measurement with a High Degree of Accuracy in an Individual Patient?

Sep 30th, 2010 8m 48s

Dr. Bloomgarden focuses on the various factors influencing A1c, and explores the issues surrounding a

Part 1. Has HbA1c Lowering Been Incorrectly Interpreted in Current Guidelines?

Sep 30th, 2010 4m 28s

Zachary Bloomgarden, MD, discusses hemoglobin A1c (HbA1c) lowering with various drugs. In a meta-analysis done, Dr. Bloomgarden and colleagues found that there was a strong relationship between baseline glycemia and the degree of fallen blood

Rate